Trial Profile
Comparative effects of bDMARDs and tofacitinib against conventional synthetic DMARDs on incident CVD in RA patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Nov 2018
Price :
$35
*
At a glance
- Drugs Tofacitinib (Primary) ; Abatacept; Anakinra; Rituximab; Tocilizumab
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- 25 Nov 2018 New trial record
- 24 Oct 2018 Results presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting